Our Passion, Your Health.

Press Releases & Events


18 March 2018

Italian pharmaceutical R&D excellence at the 33rd Congress of the European Association of Urology

Copenhagen, March 18, 2018 – Fidia farmaceutici today announced the positive results from a phase II trial evaluating efficacy and tolerability of Oncofid®P-B, an innovative Paclitaxel-Hyaluronan Bioconjugate targeted to cancer cells, in patients with primary or recurrent Ta G1-G2 papillary bladder cancer.

8 May 2017

HYMOVIS®: An Innovation In Ha-Based Viscoelastic Hydrogel Technology In The Treatment Of Osteoarthritis Knee Pain

PARSIPPANY, NJ, May 8, 2017 - Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronan (HA) - based products and its wholly owned subsidiary, Fidia Pharma USA Inc., announces their presence at the American Medical Society for Sports Medicine (AMSSM) 2017 Annual Meeting with an educational symposium on Thursday, May


Recent Events

5 July 2016

Fidia Presents New Data on HYMOVIS® , a Breakthrough in Viscoelastic Technology, at the American Orthopaedic Society for Sports Medicine 2016 Annual Meeting

HYMOVIS® is a highly viscoelastic hydrogel (HYADD®4) engineered using a proprietary process that increases lubrication and shock absorption properties; new data demonstrating long-term benefits of Hymovis® in alleviating osteoarthritis knee pain and stiffness and improving physical function and quality of life will be presented.
PARSIPPANY, N.J., July 5, 2016 – Fidia Farmaceutici S.p.A., a world leader

Our Four Leading Principles:





Have Knee Pain?

Diagnosed with OSTEOARTHRITIS (OA) of the knee?

You may be eligible to participate in a clinical trial